Revvity, Inc. (RVTY), a key player in the biotech market, has been in the spotlight recently following a range of developments. The company's strong Q4 earnings and revenues beat estimates. Revvity’s stock price has been fluctuating. Analysts like Baird and Stifel have maintained their outperform and hold recommendations on the student, respectively. However,
JP Morgan lowered the price target to $96, considering certain challenges. Several investment firms like Allspring Global Investments Holdings LLC which has raised its holdings in Revvity and Artisan Mid Cap Value Fund and Tudor Investment Corp have shown confidence in the company's future prospects. The CEO of Revvity has acknowledged challenges in its
Immunodiagnostics business in China, while the company's bullish earnings narratives faced a setback due to a one-off loss. The market reacted with mixed feelings to the cautious outlook of Revvity and pushback on Executive Stock-Retention Rules.
Barclays PLC sold a significant number of shares, causing further volatility. The company, however, showed strong potential with its new Imaging Innovation Center's launch. Amid these developments, it has been given a consensus recommendation of 'Hold' by brokerages.
Revvity RVTY News Analytics from Mon, 28 Jul 2025 07:00:00 GMT to Sat, 04 Apr 2026 10:15:57 GMT -
Rating 0
- Innovation 4
- Information 7
- Rumor -4
